Navigation Links
MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
Date:11/17/2010

GAITHERSBURG, Md., Nov. 17, 2010 /PRNewswire/ -- MedImmune announced the winners of its 5th Annual Research Abstract Competition highlighting the work of the next generation of scientific leaders performing research in areas of respiratory, inflammation and autoimmune (RIA) disease. Graduate students and postdoctoral fellows from around the world were invited to submit abstracts on RIA research as part of a competition sponsored by MedImmune, AstraZeneca's global biologics unit.

First prize of $2,000 was awarded to Jennifer Martinez, Ph.D., Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, for her research topic "The role of LC3- associated phagocytosis in the clearance of dead cells."

Martinez noted: "I am appreciative for the recognition and the opportunity to present my data.  It was also a great chance to learn about research in the field my colleagues are doing around the world."  

Second and third prizes of $1,000 and $500 were awarded respectively to Jeremy Di Domizio, Ph.D., Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, and Donald Simons, Ph.D., of The Wistar Institute, Philadelphia.

"We are impressed by the quality of research that is being conducted by young scientists," said Bahija Jallal, executive vice president of research and development at MedImmune. "This competition, which is one of the many activities MedImmune leads to engage emerging scientists in advancing health and science education, uncovered some extraordinary ideas that could help researchers further understand approaches in the RIA therapeutic area."

The competition was open to graduate students and postdoctoral fellows worldwide, with ten finalists selected to present their research to a panel of MedImmune experts at the company's headquarters in Gaithersburg.  Evaluation of abstracts were based on the following criteria: scientific rationale, description of methodology, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall presentation.

About MedImmuneMedImmune, the worldwide biologics unit for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

Notes to Editors:First Place:  Jennifer Martinez, Ph.D., Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, for her research topic "The role of LC3- associated phagocytosis in the clearance of dead cells."

Second Place:  Jeremy Di Domizio, Ph.D., Department of Immunology, M D Anderson, Houston. The title of his abstract is "A novel class of host-derived etiological agent for autoimmunity: oligomers of endogenous proteins complex with self-nucleic acids and trigger Type I interferon production by plasmacytoid dendritic cells."

Third Place:  Donald Simons, Ph.D., of The Wistar Institute, Philadelphia. The title of his abstract is "Monocytes promote the formation of Th17 cells in inflammatory arthritis."Media Contact:Karen Lancaster(301) 398-5864
'/>"/>

SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune Focused on Revolutionizing Cancer Care
2. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
3. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
4. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
5. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
6. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):